Salman Fazal

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial”.

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial

Blood(2020)10.1182/blood.2020004823

N/A

7.0DataRank · unranked

307 citations

Miguel‐Angel Perales, Mark A. Schroeder, Haris Ali, Nirav N. Shah, Yi‐Bin Chen +8 more

A phase II study of CPX-351 in younger patients < 60 years old with secondary acute myeloid leukemia: Trial in progress.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps7073

N/A

0DataRank · unranked

0 citations

Salman Fazal, Elizabeth A. Griffiths, James E. Thompson, Pamela J. Sung, Steven Daniel Green +8 more

The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts

Research Square(2023)10.21203/rs.3.rs-2802265/v1

N/A

0DataRank · unranked

2 citations

Jonathan P. Ling, Jian Zhang, Eric Helmenstine, Wencke Walter, Riley E. Bergman +15 more

The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts

Blood Advances(2024)10.1182/bloodadvances.2023011260

N/A

0DataRank · unranked

8 citations

Jonathan P. Ling, Jian Zhang, Eric Helmenstine, Wencke Walter, Panagiotis Tsakiroglou +19 more